Drug-Eluting Stents Added To NICE Technology Appraisal Program In UK
This article was originally published in The Gray Sheet
Executive Summary
The UK National Institute for Clinical Excellence will release its timetable for a drug-eluting stent technology assessment by the end of June, according to Chief Executive Andrew Dillon
You may also be interested in...
UK tech assessment
Stakeholders affected by the impending seventh wave of the National Institute for Clinical Excellence work program should complete the NICE 1registration form before timetables are announced at the end of June. The UK Department of Health and the Welsh Assembly Government identify stakeholders as: patient organizations; health professional groups; and manufacturers with technologies in the clinical area covered by the scope of the program guidelines. Primary care organizations and acute trusts will be selected at random and invited to participate. NICE says that the assessment will include drug-eluting stent performance for atherosclerotic events and the prevention of restenosis (2"The Gray Sheet" May 27, 2002, p. 10)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”